为评估盆旁淋巴结状态对FIGO分期IIIC1期宫颈癌的影响，我们进行了一项回顾性研究。研究时间为2009年6月1日至2018年12月31日。研究对象为分期为IIIC1期的宫颈癌患者，根据盆旁淋巴结累及的情况分为两组。选择III A或III B期患者作为对照组。主要结果为总生存期（OS）和无进展生存期（PFS）。共纳入586名患者，其中377名为IIIC1期（A组），209名为III A/III B期（B组）。与对照组相比，IIIC1期未能证明与更差的5年OS或PFS相关。在IIIC1期患者中，58.1%的患者没有盆旁淋巴结累及（A1组），41.9%的患者有盆旁淋巴结累及（A2组）。与A2组相比，A1组患者的5年OS（79.09% vs. 59.43%, p<0.001）和PFS（73.27% vs. 56.95%, p=0.0002）有更好的预后。然而，与B组相比，A1组患者的预后在OS和PFS方面都更好。A2组患者的预后与B组在OS和PFS方面相当。将没有盆旁淋巴结累及的IIIC1期宫颈癌再分主分期是更合适和提高辨识能力的。©2023年。亚洲妇产科肿瘤学会、韩国妇产科肿瘤学会和日本妇产科肿瘤学会。

To evaluate the effect of parametrial status on FIGO stage IIIC1 cervical cancer.A retrospective study was conducted from June 1, 2009, to December 31, 2018.Patients with stage IIIC1 cervical cancer were included and stratified into two groups based on the status of parametrial involvement. Patients with IIIA or IIIB were selected as control. The primary outcomes are overall survival (OS) and progression-free survival (PFS).Of 586 patients included, 377 patients were stage IIIC1 (group A) and 209 patients were stage IIIA/IIIB (group B). Compared control, stage IIIC1 was not associated with worse 5-year OS or PFS. Of the stage IIIC1 patients, 58.1% without parametrial involvement (group A1) and 41.9% with parametrial involvement (group A2). Patients of group A1 showed a better prognosis than group A2 both in 5-year rates of OS (79.09% vs. 59.43%, p<0.001) and PFS (73.27% vs. 56.95%, p=0.0002). However, patients of group A1 showed a better prognosis than group B both in OS and PFS. Also, patients of group A2 showed a comparable prognosis to group B both in OS and PFS.Reclassification of stage IIIC1 cervical cancer without parametrial into a new stage is more appropriate and improves discriminatory ability.© 2023. Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology, and Japan Society of Gynecologic Oncology.